Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hodgkin Lymphoma
•
Hematology
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?
Related Questions
How do you decide between treatment with ABVD vs A + AVD in a patient in their 70s with advanced stage 4 classical Hodgkin lymphoma?
Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?
What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?
Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?
What is your treatment approach for HIV-associated large B-cell lymphoma (DLBCL) with secondary CNS involvement?
How would you treat cold agglutinin disease secondary to underlying marginal zone lymphoma with only bone marrow involvement and no disease elsewhere?
Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?
How do you treat R/R T cell Histiocyte rich large b cell lymphoma?
Is there an optimal salvage radiation dose for relapsed post-CART disease?